Penelope H Dennehy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3477284/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Infectious Gastroenteritis. , 2019, , 157-168.		2
2	Nephrotoxicity With Vancomycin in the Pediatric Population. Pediatric Infectious Disease Journal, 2018, 37, 654-661.	2.0	48
3	Adverse Events Following Vaccination With Bivalent rLP2086 (Trumenba®): An Observational, Longitudinal Study During a College Outbreak and a Systematic Review. Pediatric Infectious Disease Journal, 2018, 37, e13-e19.	2.0	22
4	Multifaceted but Invisible: Perceptions of the Value of a Pediatric Cognitive Specialty. Hospital Pediatrics, 2018, 8, 385-393.	1.3	6
5	Rapid response to a college outbreak of meningococcal serogroup B disease: Nation's first widespread use of bivalent rLP2086 vaccine. Journal of American College Health, 2017, 65, 294-296.	1.5	21
6	Hydrocortisone, Vitamin C and Thiamine for Sepsis. Chest, 2017, 152, 689-690.	0.8	2
7	Adherence to Latent Tuberculosis Infection Treatment in a Population with a High Number of Refugee Children. Rhode Island Medical Journal (2013), 2017, 100, 34-38.	0.2	3
8	In-Depth Analysis of Oral versus Parenteral Therapy in Pediatric Acute Hematogenous Osteomyelitis. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
9	A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis. Journal of the Pediatric Infectious Diseases Society, 2016, 5, 53-62.	1.3	99
10	Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease. Obstetrical and Gynecological Survey, 2015, 70, 489-490.	0.4	1
11	Rapid Response to a Rhode Island College Outbreak of Meningococcal Serogroup B Disease: Nation's First Widespread use of Trumenba Vaccine. Open Forum Infectious Diseases, 2015, 2, .	0.9	3
12	Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease. New England Journal of Medicine, 2015, 372, 933-943.	27.0	571
13	Rotavirus Infection. Infectious Disease Clinics of North America, 2015, 29, 617-635.	5.1	35
14	Analysis by rotavirus gene 6 reverse transcriptase-polymerase chain reaction assay of rotavirus-positive gastroenteritis cases observed during the vaccination phase of the Rotavirus Efficacy and Safety Trial (REST). Human Vaccines and Immunotherapeutics, 2014, 10, 2267-2275.	3.3	6
15	Treatment and Prevention of Rotavirus Infection in Children. Current Infectious Disease Reports, 2013, 15, 242-250.	3.0	15
16	Tribute to Caren Hall. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 93-96.	1.3	0
17	Differential Profiles and Inhibitory Effect on Rotavirus Vaccines of Nonantibody Components in Breast Milk From Mothers in Developing and Developed Countries. Pediatric Infectious Disease Journal, 2013, 32, 863-870.	2.0	52
18	Effects of vaccine on rotavirus disease in the pediatric population. Current Opinion in Pediatrics, 2012, 24, 76-84.	2.0	45

#	Article	IF	CITATIONS
19	Prevalence and Characteristics of Human Metapneumovirus Infection Among Hospitalized Children at High Risk for Severe Lower Respiratory Tract Infection. Journal of the Pediatric Infectious Diseases Society, 2012, 1, 212-222.	1.3	39
20	Rotavirus Infection. Advances in Pediatrics, 2012, 59, 47-74.	1.4	22
21	Antigenemia, RNAemia, and innate immunity in children with acute rotavirus diarrhea. FEMS Immunology and Medical Microbiology, 2012, 64, 382-391.	2.7	26
22	Oral Acyclovir Suppression and Neurodevelopment after Neonatal Herpes. New England Journal of Medicine, 2011, 365, 1284-1292.	27.0	274
23	Viral Gastroenteritis in Children. Pediatric Infectious Disease Journal, 2011, 30, 63-64.	2.0	72
24	Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Hum Vaccin, 2011, 7, 563-568.	2.4	31
25	Inhibitory Effect of Breast Milk on Infectivity of Live Oral Rotavirus Vaccines. Pediatric Infectious Disease Journal, 2010, 29, 919-923.	2.0	130
26	Moving toward Elimination of Healthcare-Associated Infections: A Call to Action. Infection Control and Hospital Epidemiology, 2010, 31, 1101-1105.	1.8	63
27	Effectiveness of rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis in young children in Connecticut, USA. Vaccine, 2010, 28, 7501-7506.	3.8	42
28	Moving toward elimination of healthcare-associated infections: A call to action. American Journal of Infection Control, 2010, 38, 671-675.	2.3	42
29	Rotavirus. , 2010, , 347-360.		1
30	Community-acquired pneumonia in children. Medicine and Health, Rhode Island, 2010, 93, 211-5.	0.1	2
31	ACTIVE IMMUNIZING AGENTS. , 2009, , 3340-3400.		2
32	Prevalence of group C rotavirus among children in Rhode Island, United States. Journal of Clinical Virology, 2008, 42, 221-224.	3.1	23
33	Coadministration of RIX4414 Oral Human Rotavirus Vaccine Does Not Impact the Immune Response to Antigens Contained in Routine Infant Vaccines in the United States. Pediatrics, 2008, 122, e1062-e1066.	2.1	45
34	Rotavirus Vaccines: an Overview. Clinical Microbiology Reviews, 2008, 21, 198-208.	13.6	275
35	Community Outbreak of <i>Mycoplasma pneumoniae</i> Infection: Schoolâ€Based Cluster of Neurologic Disease Associated with Household Transmission of Respiratory Illness. Journal of Infectious Diseases, 2008, 198, 1365-1374.	4.0	57
36	Rotavirus Infection Alters Peripheral T-Cell Homeostasis in Children with Acute Diarrhea. Journal of Virology, 2007, 81, 3904-3912.	3.4	53

PENELOPE H DENNEHY

#	Article	IF	CITATIONS
37	Rotavirus vaccines—An update. Vaccine, 2007, 25, 3137-3141.	3.8	88
38	The integrated Phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases, 2007, 11, S36-S42.	3.3	57
39	Pediatric Immunizations: What's New in 2007. Pediatric Annals, 2007, 36, 317-324.	0.8	0
40	Rotavirus vaccines - success after failure. Medicine and Health, Rhode Island, 2007, 90, 321-4.	0.1	2
41	A short report on the highlights of world-wide development of RIX4414: a North American experience. Vaccine, 2006, 24, 3780-3781.	3.8	14
42	Rhesus Rotavirus Vaccine Effectiveness and Factors Associated With Receipt of Vaccine. Pediatric Infectious Disease Journal, 2006, 25, 1013-1018.	2.0	19
43	A Case-Control Study to Determine Risk Factors for Hospitalization for Rotavirus Gastroenteritis in U.S. Children. Pediatric Infectious Disease Journal, 2006, 25, 1123-1131.	2.0	112
44	Rotavirus Vaccines: An Update. Pediatric Infectious Disease Journal, 2006, 25, 839-840.	2.0	6
45	Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine. New England Journal of Medicine, 2006, 354, 23-33.	27.0	1,730
46	Comparative Evaluation of Safety and Immunogenicity of Two Dosages of an Oral Live Attenuated Human Rotavirus Vaccine. Pediatric Infectious Disease Journal, 2005, 24, 481-488.	2.0	94
47	SAFETY AND IMMUNOGENICITY OF PALIVIZUMAB (SYNAGIS) ADMINISTERED FOR TWO SEASONS. Pediatric Infectious Disease Journal, 2005, 24, 1021-1023.	2.0	36
48	Rotavirus vaccines: an update. Current Opinion in Pediatrics, 2005, 17, 88-92.	2.0	34
49	Acute Diarrheal Disease in Children: Epidemiology, Prevention, and Treatment. Infectious Disease Clinics of North America, 2005, 19, 585-602.	5.1	54
50	Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. Journal of Pediatrics, 2004, 144, 184-190.	1.8	138
51	Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatric Infectious Disease Journal, 2004, 23, 132-137.	2.0	364
52	Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatric Infectious Disease Journal, 2003, 22, 914-920.	2.0	62
53	Rotavirus Vaccine and Intussusception. Infectious Disease Clinics of North America, 2001, 15, 189-207.	5.1	16
54	Active Immunization in the United States: Developments over the Past Decade. Clinical Microbiology Reviews, 2001, 14, 872-908.	13.6	21

PENELOPE H DENNEHY

#	Article	IF	CITATIONS
55	Transmission of rotavirus and other enteric pathogens in the home. Pediatric Infectious Disease Journal, 2000, 19, S103-S105.	2.0	161
56	Evaluation of the ImmunoCardSTAT! Rotavirus Assay for Detection of Group A Rotavirus in Fecal Specimens. Journal of Clinical Microbiology, 1999, 37, 1977-1979.	3.9	35
57	Serologic responses by immunoblot following natural infection with rotavirus serotypes G1 and G4 in children. , 1998, 56, 52-57.		6
58	Standardization of gastric aspirate technique improves yield in the diagnosis of tuberculosis in children. Pediatric Infectious Disease Journal, 1997, 16, 222-226.	2.0	64
59	Comparative Evaluation of Reactogenicity and Immunogenicity of Two Dosages of Oral Tetravalent Rhesus Rotavirus Vaccine. Pediatric Infectious Disease Journal, 1996, 15, 1012-1018.	2.0	18
60	RECOMMENDATIONS FOR HOSPITAL VISITATION BY RECIPIENTS OF VARICELLA VACCINE. Pediatric Infectious Disease Journal, 1996, 15, 475.	2.0	0
61	First Detection of Group C Rotavirus in Fecal Specimens of Children with Diarrhea in the United States. Journal of Infectious Diseases, 1995, 172, 45-50.	4.0	110
62	Evaluation of a new enzyme immunoassay (TESTPACK rotavirus) for the detection of rotavirus in fecal specimens. Diagnostic Microbiology and Infectious Disease, 1988, 11, 201-203.	1.8	4
63	Disseminated intravascular coagulation and purpura fulminans in a patient with Candida sepsis. Biopsy of purpura fulminans as an aid to diagnosis of systemic candida infection. American Journal of Medicine, 1986, 80, 679-684.	1.5	29
64	Risk Factors Associated With Nosocomial Rotavirus Infection. JAMA Pediatrics, 1985, 139, 935.	3.0	27
65	A newborn infant with bilious vomiting and jitteriness. Journal of Pediatrics, 1985, 106, 161-166.	1.8	2
66	Pneumococcal pneumonia in Rhode Island: Implications for vaccine use. Journal of Infection, 1982, 4, 229-235.	3.3	2